Searched for
REMOGLIFLOZIN ETABONATE
For investors looking beyond the short-term horizon: 5 mid-cap stocks from different sectors with upside potential up to 28%All is once again quiet on the US-Iran war front, and some kind of dialogue to resolve the issues between the two seems to be still underwa...- These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Will the currency cycle help them? Yes, but very selectively: 10 pharma stocks with upside potential of up to 33%The biggest mistake made in currency cycles is to confuse revenue gain with pure earnings gain. A company may report stronger rupee revenue...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 41%The bears seem to have friends on the street who come to their rescue out of nowhere. For instance, the sudden developments in the AI space...
- Stock picks of the week: Stocks with consistent score improvement and return potential of more than 36% in 1 yearThe way the Nifty and Sensex moved on Friday will make many think of volatility again. But it could have been just profit-booking after a s...
- Pharma stocks: With headwinds of uncertainty over, will they outperform? 7 stocks with an upside potential of up to 43%When it is Trump, logic usually flies out of the window. There is, indeed, little that is logical about the reciprocal tariffs he has annou...
- Stock picks of the week: 5 stocks with consistent score improvement and an upside potential of up to 36%The volatility quotient has been high for the last couple of weeks. But with the Q3 earning season winding down, things may cool down a bit...
- Stock picks of the week: 5 stocks with consistent score improvement and an upside potential of up to 48%Once again the global markets have been hit by Trump’s tariff tantrums. Now, let’s leave aside the global development, which was partly exp...
- Delhi High Court seeks response from govt, NPPA on Glenmark's pleaDelhi High Court hears Glenmark Pharma's petition against NPPA's pricing order for anti-diabetic drugs, claiming arbitrary pricing and seek...
- On a path to recovery; 7 mid-cap pharma stocks with an upside potential up to 47 %After the covid tailwinds got over, pharma stocks witnessed a phase of under-performance. However as the markets get jittery, select pharma...
- Weekly Top Picks: 5 stocks with an upside potential of up to 39%Budget 2023, RBI policy and events around Adani group ensured that Nifty stays in volatile mode with bearish bias. However, even during thi...
- These 5 midcap stocks with ‘strong buy’ & ‘buy’ ratings can rally over 25%, say analystsFor all those who are busy guessing what will happen to Adani group stocks, there is a market beyond Adani stocks and that is very large. E...
- Defensive Bets: 4 midcaps from pharma sector with ‘Buy’ & ‘Strong Buy’ ratings have upside potential of up to 31%As NIFTY gets even more volatile, there are some sectors which are traditionally considered defensive and they tend to get attention when m...
- 7 midcap stocks, 1 with “Strong Buy” and 6 with “Buy” recommendations with potential upside of up to 30%Four pharma companies, a southern india focussed real estate player to mid-cap software company have seen an improvement in their overall s...
- Glenmark launches unique fixed dose combination drug for diabetesThe Mumbai based drug firm said it has introduced fixed dose combination (FDC) of its novel, patent protected Sodium Glucose Co-Transporter...
- Violation of drug price control order: Drug cos under NPPA lens for self-exemption from price capPricing watchdog has found that companies such as Lupin and Boehringer Ingelheim launched products bypassing the regulatory framework. The ...
- Glenmark Pharma launches anti-diabetes drug Remogliflozin in IndiaGlenmark said it will commercialise Remogliflozin in India under the brand names 'Remo' and 'Remozen'.
Load More
